What is BioScience Health Innovations Inc's earnings per share (EPS)?

BioScience Health Innovations Inc (BHIC) reported diluted earnings per share of $0.06 for fiscal year 2025. This represents a 500.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BioScience Health Innovations Inc Financials

BHIC

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows BioScience Health Innovations Inc (BHIC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BHIC FY2025 2026-04-22

BHIC's profit inflection now reflects fixed-cost absorption on rapid sales growth, while working capital still delays cash capture.

Across the last two valid years, operating margin moved to 12.6% from -42.1% even as gross margin compressed. That combination points to scale covering overhead, not richer unit economics: the company became profitable because expenses grew more slowly than sales.

FY2025 earnings did not convert cleanly into liquidity: operating cash flow was $172K versus net income of $642K. The likely explanation is a working-capital build, with much more cash tied up in receivables and inventory as the business expanded.

The balance sheet now carries equity of $1.5M against just liabilities of $230K, a major shift from the earlier negative-equity structure. Cash stayed near $662K even while financing cash turned negative, suggesting the company was no longer depending on new outside funding just to keep liquidity steady.

Financial Health Signals

Financial Profile 50/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of BioScience Health Innovations Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

BioScience Health Innovations Inc has an operating margin of 12.6%, meaning the company retains $13 of operating profit per $100 of revenue. This below-average margin results in a low score of 21/100, suggesting thin profitability after operating expenses. This is up from 4.7% the prior year.

Growth

100

BioScience Health Innovations Inc's revenue surged 208.3% year-over-year to $5.7M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

BioScience Health Innovations Inc carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Returns

BioScience Health Innovations Inc earns a strong 43.5% return on equity (ROE), meaning it generates $43 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 80/100. This is up from 10.4% the prior year.

Piotroski F-Score Neutral

5/9

BioScience Health Innovations Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.27x

For every $1 of reported earnings, BioScience Health Innovations Inc generates $0.27 in operating cash flow ($172K OCF vs $642K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.7M

YoY+208.3%

BioScience Health Innovations Inc generated $5.7M in revenue in fiscal year 2025. This represents an increase of 208.3% from the prior year.

EBITDA

N/A

Net Income

$642K

YoY+638.0%

BioScience Health Innovations Inc reported $642K in net income in fiscal year 2025. This represents an increase of 638.0% from the prior year.

EPS (Diluted)

$0.06

YoY+500.0%

BioScience Health Innovations Inc earned $0.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 500.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$662K

YoY-0.1%

5Y CAGR+100.1%

BioScience Health Innovations Inc held $662K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

11M

YoY+0.0%

5Y CAGR+15.0%

BioScience Health Innovations Inc had 11M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

57.0%

YoY-14.0pp

BioScience Health Innovations Inc's gross margin was 57.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 14.0 percentage points from the prior year.

Operating Margin

12.6%

YoY+7.9pp

BioScience Health Innovations Inc's operating margin was 12.6% in fiscal year 2025, reflecting core business profitability. This is up 7.9 percentage points from the prior year.

Net Margin

11.3%

YoY+6.6pp

BioScience Health Innovations Inc's net profit margin was 11.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 6.6 percentage points from the prior year.

Return on Equity

43.5%

YoY+33.0pp

5Y CAGR+103.4pp

BioScience Health Innovations Inc's ROE was 43.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 33.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$161K

YoY+522.8%

BioScience Health Innovations Inc invested $161K in research and development in fiscal year 2025. This represents an increase of 522.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BHIC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$5.7M+208.3%	$1.8M+208.7%	$598K+761.8%	$69K	$0	$0
Cost of Revenue	$2.4M+356.6%	$536K+373.6%	$113K+1067.0%	$10K	N/A	N/A
Gross Profit	$3.2M+147.6%	$1.3M+170.2%	$484K+712.2%	$60K	N/A	N/A
R&D Expenses	$161K+522.8%	$26K	$0	N/A	N/A	N/A
SG&A Expenses	$2.2M+92.5%	$1.1M+62.3%	$706K+366.7%	$151K+490.9%	$26K+233.4%	$8K
Operating Income	$719K+726.5%	$87K+134.6%	-$252K-47.6%	-$170K-565.6%	-$26K-233.4%	-$8K
Interest Expense	N/A	N/A	N/A	N/A	$450	N/A
Income Tax	$77K	$0	$0	$0	$0	$0
Net Income	$642K+638.0%	$87K+134.6%	-$252K-47.6%	-$170K-565.6%	-$26K-233.4%	-$8K
EPS (Diluted)	$0.06+500.0%	$0.01+200.0%	$-0.01	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.6M+39.0%	$1.1M-35.6%	$1.8M+43.2%	$1.2M+101.1%	$610K+6.5%	$573K+49.1%	$384K+38.4%	$278K
Cost of Revenue	$1.0M+131.0%	$433K-36.6%	$683K+106.4%	$331K+22.0%	$271K+83.0%	$148K+100.9%	$74K+72.3%	$43K
Gross Profit	$572K-18.1%	$698K-35.0%	$1.1M+19.9%	$896K+164.3%	$339K-20.2%	$425K+36.8%	$310K+32.2%	$235K
R&D Expenses	N/A	N/A	N/A	$38K	N/A	N/A	N/A	$805
SG&A Expenses	$656K+13.8%	$577K+6.8%	$540K+24.6%	$434K+44.4%	$300K-13.1%	$345K+55.1%	$223K-20.0%	$278K
Operating Income	-$157K-1684.0%	-$9K-101.9%	$458K+7.2%	$427K+4186.4%	$10K-82.3%	$56K-24.3%	$74K+239.0%	-$53K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A
Net Income	-$234K-2560.3%	-$9K-101.9%	$458K+7.2%	$427K+4186.4%	$10K-82.3%	$56K-24.3%	$74K+239.0%	-$53K
EPS (Diluted)	N/A	$0.00	$0.010.0%	$0.01	N/A	$0.01	$0.00	$0.00

BHIC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.7M+95.4%	$874K+835.7%	$93K+195.5%	$32K+400.6%	$6K-69.4%	$21K
Current Assets	$1.6M+83.9%	$848K+807.8%	$93K+195.5%	$32K+400.6%	$6K-69.4%	$21K
Cash & Equivalents	$662K-0.1%	$663K+3343.8%	$19K+66.3%	$12K+468.5%	$2K-90.1%	$21K
Inventory	$336K+476.7%	$58K+54.7%	$38K+207.1%	$12K	N/A	N/A
Accounts Receivable	$399K+298.1%	$100K+175.1%	$36K+369.6%	$8K	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$230K+496.3%	$39K-61.5%	$100K+105.3%	$49K+155.4%	$19K+144.6%	$8K
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.5M+76.9%	$835K+12455.6%	-$7K+60.7%	-$17K-34.3%	-$13K-199.8%	$13K
Retained Earnings	$301K+188.3%	-$341K+20.3%	-$428K-142.4%	-$177K-416.4%	-$34K-298.4%	-$9K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.7M-17.4%	$2.1M+0.5%	$2.1M+47.5%	$1.4M+59.6%	$874K+110.1%	$416K+94.7%	$214K+38.0%	$155K
Current Assets	$1.6M-21.9%	$2.0M+0.5%	$2.0M+48.3%	$1.3M+57.9%	$848K+107.4%	$409K+91.4%	$214K+38.0%	$155K
Cash & Equivalents	$662K-41.9%	$1.1M-12.3%	$1.3M+26.4%	$1.0M+55.2%	$663K+98.8%	$333K+131.5%	$144K+54.9%	$93K
Inventory	$336K-55.6%	$758K+204.8%	$249K+15.2%	$216K+269.9%	$58K+38.1%	$42K+4.0%	$41K+0.4%	$40K
Accounts Receivable	$399K+531.6%	$63K-83.8%	$390K+317.4%	$93K-6.8%	$100K+214.2%	$32K+15.5%	$28K+28.9%	$21K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$230K-35.5%	$356K+5.5%	$338K+154.0%	$133K+244.8%	$39K-15.4%	$46K+85.8%	$25K-38.6%	$40K
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.5M-13.7%	$1.7M-0.5%	$1.7M+36.3%	$1.3M+51.1%	$835K+125.6%	$370K+95.8%	$189K+64.6%	$115K
Retained Earnings	$301K-43.7%	$535K-1.6%	$543K+534.0%	$86K+125.1%	-$341K+2.8%	-$351K+13.8%	-$407K+15.4%	-$481K

BHIC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$172K+642.5%	$23K+107.5%	-$308K-68.4%	-$183K-520.9%	-$29K-283.2%	-$8K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$57K-118.3%	-$26K	$0	$0	N/A	$0
Financing Cash Flow	-$116K-117.9%	$646K+104.8%	$316K+62.4%	$194K+1691.1%	$11K-61.7%	$28K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$101K+70.4%	-$340K-219.5%	$285K-13.2%	$328K+752.6%	-$50K-196.3%	$52K-24.6%	$69K+244.3%	-$48K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$11K	$0+100.0%	-$16K+46.5%	-$30K-57.9%	-$19K-170.0%	-$7K	$0	$0
Financing Cash Flow	-$366K-302.8%	$180K+8416.3%	$2K-96.9%	$68K-83.1%	$399K+176.6%	$144K+886.9%	-$18K-115.0%	$122K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BHIC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	57.0%-14.0pp	70.9%-10.1pp	81.1%-4.9pp	86.0%	N/A	N/A
Operating Margin	12.6%+7.9pp	4.7%+46.8pp	-42.1%+203.7pp	-245.8%	N/A	N/A
Net Margin	11.3%+6.6pp	4.7%+46.8pp	-42.1%+203.7pp	-245.8%	N/A	N/A
Return on Equity	43.5%+33.0pp	10.4%	N/A	N/A	N/A	-59.9%
Return on Assets	37.6%+27.6pp	10.0%+279.3pp	-269.3%+269.9pp	-539.3%-133.7pp	-405.6%-368.4pp	-37.2%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.16+0.1	0.05+14.9	-14.81-12.0	-2.84-1.3	-1.49-2.1	0.61
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	36.4%-25.4pp	61.7%+0.6pp	61.1%-11.9pp	73.0%+17.5pp	55.6%-18.6pp	74.1%-6.7pp	80.8%-3.8pp	84.6%
Operating Margin	-10.0%-9.2pp	-0.8%-26.8pp	26.0%-8.7pp	34.8%+33.1pp	1.6%-8.2pp	9.8%-9.5pp	19.3%+38.6pp	-19.2%
Net Margin	-14.8%-14.1pp	-0.8%-26.8pp	26.0%-8.7pp	34.8%+33.1pp	1.6%-8.2pp	9.8%-9.5pp	19.3%+38.6pp	-19.2%
Return on Equity	-15.8%-15.3pp	-0.5%-27.1pp	26.6%-7.2pp	33.8%+32.6pp	1.2%-14.0pp	15.2%-24.1pp	39.3%+85.7pp	-46.5%
Return on Assets	-13.7%-13.3pp	-0.4%-22.7pp	22.3%-8.3pp	30.6%+29.5pp	1.1%-12.4pp	13.5%-21.2pp	34.8%+69.2pp	-34.5%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.16-0.1	0.21+0.0	0.20+0.1	0.11+0.1	0.05-0.1	0.120.0	0.13-0.2	0.35
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is BioScience Health Innovations Inc's annual revenue?

BioScience Health Innovations Inc (BHIC) reported $5.7M in total revenue for fiscal year 2025. This represents a 208.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BioScience Health Innovations Inc's revenue growing?

BioScience Health Innovations Inc (BHIC) revenue grew by 208.3% year-over-year, from $1.8M to $5.7M in fiscal year 2025.

Is BioScience Health Innovations Inc profitable?

Yes, BioScience Health Innovations Inc (BHIC) reported a net income of $642K in fiscal year 2025, with a net profit margin of 11.3%.

What is BioScience Health Innovations Inc's gross margin?

BioScience Health Innovations Inc (BHIC) had a gross margin of 57.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is BioScience Health Innovations Inc's operating margin?

BioScience Health Innovations Inc (BHIC) had an operating margin of 12.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is BioScience Health Innovations Inc's net profit margin?

BioScience Health Innovations Inc (BHIC) had a net profit margin of 11.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is BioScience Health Innovations Inc's return on equity (ROE)?

BioScience Health Innovations Inc (BHIC) has a return on equity of 43.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BioScience Health Innovations Inc's operating cash flow?

BioScience Health Innovations Inc (BHIC) generated $172K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are BioScience Health Innovations Inc's total assets?

BioScience Health Innovations Inc (BHIC) had $1.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does BioScience Health Innovations Inc spend on research and development?

BioScience Health Innovations Inc (BHIC) invested $161K in research and development during fiscal year 2025.

How many shares does BioScience Health Innovations Inc have outstanding?

BioScience Health Innovations Inc (BHIC) had 11M shares outstanding as of fiscal year 2025.

What is BioScience Health Innovations Inc's debt-to-equity ratio?

BioScience Health Innovations Inc (BHIC) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BioScience Health Innovations Inc's return on assets (ROA)?

BioScience Health Innovations Inc (BHIC) had a return on assets of 37.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BioScience Health Innovations Inc's Piotroski F-Score?

BioScience Health Innovations Inc (BHIC) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BioScience Health Innovations Inc's earnings high quality?

BioScience Health Innovations Inc (BHIC) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is BioScience Health Innovations Inc?

BioScience Health Innovations Inc (BHIC) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.